文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

老年(≥70 岁)可手术原发性三阴性乳腺癌的预后因素和模型:来自国家癌症数据库的分析。

Prognostic Factors and Models for Elderly (≥70 Years Old) Primary Operable Triple-Negative Breast Cancer: Analysis From the National Cancer Database.

机构信息

Department of Breast Surgery, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.

Department of Pathology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.

出版信息

Front Endocrinol (Lausanne). 2022 Mar 17;13:856268. doi: 10.3389/fendo.2022.856268. eCollection 2022.


DOI:10.3389/fendo.2022.856268
PMID:35370936
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8969604/
Abstract

BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. In the elderly (≥70 years old) primary operable (TNM) TNBC, individualized treatment modalities for this population are pivotal and important, but limited studies are explored. METHODS: The clinicopathological features of elderly primary operable TNBC patients were retrospectively selected from the Surveillance, Epidemiology, and End Results (SEER) database between January 2010 and December 2015. Kaplan-Meier curves were used to show the survival patterns in the different subgroups. Multivariate Cox analysis was used to identify independent risk factors in the 3-, 5-, and 7- year overall survival (OS) and cancer-specific survival (CSS) in this subpopulation. The predictive model was further developed and validated for clinical use. RESULT: Between 2010 and 2015 years, a total of 4,761 elderly primary operable TNBC patients were enrolled for the study, with a mean age of 76 years and a median follow-up of 56 months. The multivariate Cox analysis showed that age (increased per year: hazard ratio (HR) = 1.05), race (Asian/Pacific Islander and American Indian/Alaska Native, HR = 0.73), differentiation grade (grade II: HR = 2.01; grade III/IV: HR = 2.67), larger tumor size (T: HR = 1.83; T: HR = 2.78; T: HR = 4.93), positive N stage (N: HR = 1.60; N: HR = 1.54), receiving radiation therapy (HR = 0.66), and receiving adjuvant chemotherapy (HR = 0.61) were the independent prognostic factors for OS, and a similar prognostic pattern was also determined in CSS. Besides, two nomograms for predicting the 3-, 5-, and 7-year OS and CSS in this population were developed with a favorable concordance index of 0.716 and 0.746, respectively. CONCLUSION: The results highlight that both radiation and adjuvant chemotherapy are significantly associated with favorable long-term OS and CSS probability in elderly primary operable TNBC patients. Based on the determined independent prognostic factors, the novel nomograms could assist the oncologists to make individualized clinical decisions for the subpopulation at different risks.

摘要

背景:三阴性乳腺癌(TNBC)是一种侵袭性乳腺癌亚型。在老年(≥70 岁)可手术(TNM)原发性 TNBC 患者中,为该人群制定个体化治疗方案至关重要,但目前探索有限。

方法:从 2010 年 1 月至 2015 年 12 月,从监测、流行病学和最终结果(SEER)数据库中回顾性选择老年原发性可手术 TNBC 患者的临床病理特征。Kaplan-Meier 曲线用于显示不同亚组的生存模式。多变量 Cox 分析用于确定该亚群中 3 年、5 年和 7 年总生存(OS)和癌症特异性生存(CSS)的独立风险因素。进一步开发并验证预测模型以用于临床。

结果:在 2010 年至 2015 年期间,共有 4761 名老年原发性可手术 TNBC 患者入组本研究,平均年龄为 76 岁,中位随访时间为 56 个月。多变量 Cox 分析显示,年龄(每年增加:风险比(HR)=1.05)、种族(亚裔/太平洋岛民和美洲印第安人/阿拉斯加原住民,HR=0.73)、分化程度(等级 II:HR=2.01;等级 III/IV:HR=2.67)、肿瘤较大(T:HR=1.83;T:HR=2.78;T:HR=4.93)、阳性 N 期(N:HR=1.60;N:HR=1.54)、接受放疗(HR=0.66)和接受辅助化疗(HR=0.61)是 OS 的独立预后因素,CSS 也呈现出相似的预后模式。此外,还开发了两个用于预测该人群 3 年、5 年和 7 年 OS 和 CSS 的列线图,具有良好的一致性指数分别为 0.716 和 0.746。

结论:结果强调,放疗和辅助化疗均与老年原发性可手术 TNBC 患者的长期 OS 和 CSS 概率显著相关。基于确定的独立预后因素,新的列线图可以帮助肿瘤学家为不同风险的亚群做出个体化的临床决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/d045fec7e6ff/fendo-13-856268-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/caf8928f5356/fendo-13-856268-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/0ecf65b865da/fendo-13-856268-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/ae60a3aea756/fendo-13-856268-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/aff81aef84d4/fendo-13-856268-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/1ba9e7c4e41c/fendo-13-856268-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/a05dfd197030/fendo-13-856268-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/90b7eaa28985/fendo-13-856268-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/41b00295fbd5/fendo-13-856268-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/d045fec7e6ff/fendo-13-856268-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/caf8928f5356/fendo-13-856268-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/0ecf65b865da/fendo-13-856268-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/ae60a3aea756/fendo-13-856268-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/aff81aef84d4/fendo-13-856268-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/1ba9e7c4e41c/fendo-13-856268-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/a05dfd197030/fendo-13-856268-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/90b7eaa28985/fendo-13-856268-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/41b00295fbd5/fendo-13-856268-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f7c/8969604/d045fec7e6ff/fendo-13-856268-g009.jpg

相似文献

[1]
Prognostic Factors and Models for Elderly (≥70 Years Old) Primary Operable Triple-Negative Breast Cancer: Analysis From the National Cancer Database.

Front Endocrinol (Lausanne). 2022

[2]
Prognosis of Patients With Triple-negative Breast Cancer: A Population-based Study From SEER Database.

Clin Breast Cancer. 2023-4

[3]
Comprehensive study of clinical features, prognostic factors, and survival in patients with pancreatic solid pseudopapillary neoplasms based on the 2019 WHO classification.

J Cancer Res Clin Oncol. 2023-10

[4]
Prognostic nomograms and Aggtrmmns scoring system for predicting overall survival and cancer-specific survival of patients with kidney cancer.

Cancer Med. 2020-4

[5]
Geriatric Early-Stage Triple-Negative Breast Cancer Patients in Low-risk Population: Omitting Chemotherapy Based on Nomogram.

Clin Breast Cancer. 2022-12

[6]
Prognostic Factors and a Nomogram Predicting Overall Survival and Cancer-Specific Survival for Patients with Collecting Duct Renal Cell Carcinoma.

Biomed Res Int. 2021

[7]
Survival outcome assessment for triple-negative breast cancer: a nomogram analysis based on integrated clinicopathological, sonographic, and mammographic characteristics.

Eur Radiol. 2022-10

[8]
Influence of advanced age on the prognosis of triple-negative breast cancer patients: A surveillance, epidemiology, and end results-based study.

J Cancer Res Ther. 2023-4

[9]
A Clinical Model of Bone Angiosarcoma Patients: A Population-based Analysis of Epidemiology, Prognosis, and Treatment.

Orthop Surg. 2020-12

[10]
Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.

Breast Cancer Res Treat. 2018-10-19

引用本文的文献

[1]
Treatment strategies for triple-negative primary breast cancer in older women: a systematic review.

JNCI Cancer Spectr. 2025-4-30

[2]
Frequency of use and characterization of frailty assessments in observational studies on older women with breast cancer: a systematic review.

BMC Geriatr. 2024-6-27

[3]
Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment.

Front Oncol. 2023-12-15

[4]
A nomogram for individually predicting overall survival for elderly patients with early breast cancer: a consecutive cohort study.

Front Oncol. 2023-7-28

[5]
Development and validation of a predictive nomogram for the specific mortality risk of luminal B breast cancer patients: a competing risk model based on real populations.

Transl Cancer Res. 2023-4-28

本文引用的文献

[1]
Is adjuvant chemotherapy necessary in older patients with breast cancer?

Breast Cancer. 2022-5

[2]
Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients.

Breast Cancer Res Treat. 2021-9

[3]
Global incidence and mortality of breast cancer: a trend analysis.

Aging (Albany NY). 2021-2-11

[4]
Breast Cancer Mortality in Young Women in Brazil.

Front Oncol. 2021-1-25

[5]
Molecular analyses of triple-negative breast cancer in the young and elderly.

Breast Cancer Res. 2021-2-10

[6]
Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.

JAMA Oncol. 2021-3-1

[7]
Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis.

Lancet Oncol. 2020-12

[8]
Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.

JAMA Netw Open. 2020-11-2

[9]
Triple‑negative breast cancer therapy: Current and future perspectives (Review).

Int J Oncol. 2020-12

[10]
Omitting radiotherapy is safe in breast cancer patients ≥ 70 years old after breast-conserving surgery without axillary lymph node operation.

Sci Rep. 2020-11-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索